IL308274A - A method for creating hypertrophic muscle fibers to create industrial meat - Google Patents
A method for creating hypertrophic muscle fibers to create industrial meatInfo
- Publication number
- IL308274A IL308274A IL308274A IL30827423A IL308274A IL 308274 A IL308274 A IL 308274A IL 308274 A IL308274 A IL 308274A IL 30827423 A IL30827423 A IL 30827423A IL 308274 A IL308274 A IL 308274A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitor
- cells
- agonist
- receptor
- activator
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 88
- 235000013372 meat Nutrition 0.000 title claims description 35
- 230000001939 inductive effect Effects 0.000 title claims description 25
- 210000001087 myotubule Anatomy 0.000 title description 14
- 238000004519 manufacturing process Methods 0.000 title description 8
- 230000001969 hypertrophic effect Effects 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims description 132
- 230000001114 myogenic effect Effects 0.000 claims description 79
- 239000003112 inhibitor Substances 0.000 claims description 74
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 claims description 73
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 claims description 73
- 239000002243 precursor Substances 0.000 claims description 66
- 102000034527 Retinoid X Receptors Human genes 0.000 claims description 63
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 63
- 210000003098 myoblast Anatomy 0.000 claims description 63
- 230000004927 fusion Effects 0.000 claims description 60
- 239000000556 agonist Substances 0.000 claims description 59
- 239000012190 activator Substances 0.000 claims description 49
- 210000003205 muscle Anatomy 0.000 claims description 46
- 230000004069 differentiation Effects 0.000 claims description 42
- 102000003702 retinoic acid receptors Human genes 0.000 claims description 42
- 108090000064 retinoic acid receptors Proteins 0.000 claims description 42
- 102000019149 MAP kinase activity proteins Human genes 0.000 claims description 40
- 108040008097 MAP kinase activity proteins Proteins 0.000 claims description 40
- 102000042094 ryanodine receptor (TC 1.A.3.1) family Human genes 0.000 claims description 36
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 claims description 36
- 241001465754 Metazoa Species 0.000 claims description 35
- 239000002609 medium Substances 0.000 claims description 35
- 210000000130 stem cell Anatomy 0.000 claims description 33
- 102000004913 RYR1 Human genes 0.000 claims description 31
- 108060007240 RYR1 Proteins 0.000 claims description 30
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 29
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 29
- 102000004914 RYR3 Human genes 0.000 claims description 29
- 108060007242 RYR3 Proteins 0.000 claims description 29
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 29
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 29
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 29
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 29
- 230000015572 biosynthetic process Effects 0.000 claims description 27
- 230000003834 intracellular effect Effects 0.000 claims description 26
- 102000002576 MAP Kinase Kinase 1 Human genes 0.000 claims description 23
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 claims description 23
- 230000001105 regulatory effect Effects 0.000 claims description 23
- 108091000080 Phosphotransferase Proteins 0.000 claims description 22
- 102000020233 phosphotransferase Human genes 0.000 claims description 22
- 230000035755 proliferation Effects 0.000 claims description 22
- 230000011664 signaling Effects 0.000 claims description 22
- 210000002966 serum Anatomy 0.000 claims description 21
- -1 ADZ0364 Chemical compound 0.000 claims description 20
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims description 17
- HDAJDNHIBCDLQF-RUZDIDTESA-N SCH772984 Chemical compound O=C([C@@H]1CCN(C1)CC(=O)N1CCN(CC1)C=1C=CC(=CC=1)C=1N=CC=CN=1)NC(C=C12)=CC=C1NN=C2C1=CC=NC=C1 HDAJDNHIBCDLQF-RUZDIDTESA-N 0.000 claims description 17
- 102100032970 Myogenin Human genes 0.000 claims description 15
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 14
- 101000589002 Homo sapiens Myogenin Proteins 0.000 claims description 13
- 239000000835 fiber Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 claims description 12
- 239000006143 cell culture medium Substances 0.000 claims description 12
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 11
- 238000001574 biopsy Methods 0.000 claims description 10
- 210000002950 fibroblast Anatomy 0.000 claims description 10
- 210000001057 smooth muscle myoblast Anatomy 0.000 claims description 10
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims description 10
- 229960002324 trifluoperazine Drugs 0.000 claims description 10
- RZUOCXOYPYGSKL-GOSISDBHSA-N 1-[(1s)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]pyridin-2-one Chemical compound CN1N=CC=C1NC1=NC=CC(C2=CC(=O)N([C@H](CO)C=3C=C(F)C(Cl)=CC=3)C=C2)=N1 RZUOCXOYPYGSKL-GOSISDBHSA-N 0.000 claims description 9
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 claims description 9
- 208000029549 Muscle injury Diseases 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 9
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 9
- 210000000663 muscle cell Anatomy 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 claims description 8
- 210000001789 adipocyte Anatomy 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 claims description 8
- 102000000584 Calmodulin Human genes 0.000 claims description 7
- 108010041952 Calmodulin Proteins 0.000 claims description 7
- 239000003710 calcium ionophore Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- MFIHSKBTNZNJIK-RZTYQLBFSA-N (3s,3ar,6s,6ar)-3-(3,4-dimethoxyphenyl)-6-(3,4,5-trimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan Chemical compound C1=C(OC)C(OC)=CC=C1[C@@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(OC)=C(OC)C=3)[C@@H]2CO1 MFIHSKBTNZNJIK-RZTYQLBFSA-N 0.000 claims description 6
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 claims description 6
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 claims description 6
- XVECMUKVOMUNLE-UHFFFAOYSA-N 5-(2-phenyl-3-pyrazolo[1,5-a]pyridinyl)-2H-pyrazolo[3,4-c]pyridazin-3-amine Chemical compound C1=C2C(N)=NNC2=NN=C1C(=C1C=CC=CN1N=1)C=1C1=CC=CC=C1 XVECMUKVOMUNLE-UHFFFAOYSA-N 0.000 claims description 6
- ODIUJYZERXVGEI-UHFFFAOYSA-N 6-benzyl-3-pyridin-4-yl-5,8-dihydro-1H-pyrazolo[4,3-g]quinazolin-7-one Chemical compound O=C1Nc2cc3[nH]nc(-c4ccncc4)c3cc2CN1Cc1ccccc1 ODIUJYZERXVGEI-UHFFFAOYSA-N 0.000 claims description 6
- 102000010825 Actinin Human genes 0.000 claims description 6
- 108010063503 Actinin Proteins 0.000 claims description 6
- 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 claims description 6
- BQOHYSXSASDCEA-KEOHHSTQSA-N Cyclic ADP-Ribose Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C=2N=CN3C(C=2N=C1)=N)O)O)OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]3O1 BQOHYSXSASDCEA-KEOHHSTQSA-N 0.000 claims description 6
- RFWVETIZUQEJEF-UHFFFAOYSA-N GDC-0623 Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F RFWVETIZUQEJEF-UHFFFAOYSA-N 0.000 claims description 6
- 101100518997 Mus musculus Pax3 gene Proteins 0.000 claims description 6
- 101100351033 Mus musculus Pax7 gene Proteins 0.000 claims description 6
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims description 6
- BSMCAPRUBJMWDF-UHFFFAOYSA-N [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-(3-hydroxy-3-piperidin-2-ylazetidin-1-yl)methanone Chemical compound C1C(O)(C2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-UHFFFAOYSA-N 0.000 claims description 6
- 229960001445 alitretinoin Drugs 0.000 claims description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 6
- 229960002938 bexarotene Drugs 0.000 claims description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 6
- 238000010494 dissociation reaction Methods 0.000 claims description 6
- 230000005593 dissociations Effects 0.000 claims description 6
- QOTXBMGJKFVZRD-HISDBWNOSA-O nicotinic acid-adenine dinucleotide phosphate Chemical compound [N+]1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@@H]([C@@H]2O)OP(O)(O)=O)N2C=3N=CN=C(C=3N=C2)N)=CC=CC(C(O)=O)=C1 QOTXBMGJKFVZRD-HISDBWNOSA-O 0.000 claims description 6
- 229950007231 ravoxertinib Drugs 0.000 claims description 6
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims description 6
- WUTVMXLIGHTZJC-OAQYLSRUSA-N 4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide Chemical compound N1=C(C=2C=C(NC=2)C(=O)N[C@H](CO)C=2C=C(Cl)C=CC=2)C(C)=CN=C1NC1=CC=C(F)C=C1Cl WUTVMXLIGHTZJC-OAQYLSRUSA-N 0.000 claims description 5
- 239000005889 Cyantraniliprole Substances 0.000 claims description 5
- PSOVNZZNOMJUBI-UHFFFAOYSA-N chlorantraniliprole Chemical compound CNC(=O)C1=CC(Cl)=CC(C)=C1NC(=O)C1=CC(Br)=NN1C1=NC=CC=C1Cl PSOVNZZNOMJUBI-UHFFFAOYSA-N 0.000 claims description 5
- DVBUIBGJRQBEDP-UHFFFAOYSA-N cyantraniliprole Chemical compound CNC(=O)C1=CC(C#N)=CC(C)=C1NC(=O)C1=CC(Br)=NN1C1=NC=CC=C1Cl DVBUIBGJRQBEDP-UHFFFAOYSA-N 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 210000003668 pericyte Anatomy 0.000 claims description 5
- 230000008929 regeneration Effects 0.000 claims description 5
- 238000011069 regeneration method Methods 0.000 claims description 5
- 238000010186 staining Methods 0.000 claims description 5
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims description 5
- BOOOLEGQBVUTKC-NVQSDHBMSA-N (2e,4e)-3-methyl-5-[(1s,2s)-2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic acid Chemical compound OC(=O)\C=C(/C)\C=C\[C@@H]1C[C@]1(C)C1=CC=C2C(C)(C)CCC(C)(C)C2=C1 BOOOLEGQBVUTKC-NVQSDHBMSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- ZZUKALQMHNSWTK-UHFFFAOYSA-N 4-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-dioxolan-2-yl]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C1(C=2C=CC(=CC=2)C(O)=O)OCCO1 ZZUKALQMHNSWTK-UHFFFAOYSA-N 0.000 claims description 4
- JNPRPMBJODOFEC-UHFFFAOYSA-N 6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2-morpholin-4-ylethyl)thieno[2,3-c]pyrrol-4-one Chemical compound CC1(N(C(C2=C1SC(=C2)C1=NC(=NC=C1)NC1=CC=NN1C)=O)CCN1CCOCC1)C JNPRPMBJODOFEC-UHFFFAOYSA-N 0.000 claims description 4
- 241000251468 Actinopterygii Species 0.000 claims description 4
- 241000271566 Aves Species 0.000 claims description 4
- 101100239675 Danio rerio mymk gene Proteins 0.000 claims description 4
- 101100239680 Danio rerio mymx gene Proteins 0.000 claims description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 4
- 229940124647 MEK inhibitor Drugs 0.000 claims description 4
- 101150094019 MYOG gene Proteins 0.000 claims description 4
- 101100239677 Mus musculus Mymk gene Proteins 0.000 claims description 4
- 101100239682 Mus musculus Mymx gene Proteins 0.000 claims description 4
- 108010009711 Phalloidine Proteins 0.000 claims description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 4
- 210000002449 bone cell Anatomy 0.000 claims description 4
- 239000000801 calcium channel stimulating agent Substances 0.000 claims description 4
- 210000003321 cartilage cell Anatomy 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 4
- 238000001964 muscle biopsy Methods 0.000 claims description 4
- 230000004070 myogenic differentiation Effects 0.000 claims description 4
- MRWQRJMESRRJJB-UHFFFAOYSA-N pentifylline Chemical compound O=C1N(CCCCCC)C(=O)N(C)C2=C1N(C)C=N2 MRWQRJMESRRJJB-UHFFFAOYSA-N 0.000 claims description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 4
- 239000012679 serum free medium Substances 0.000 claims description 4
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 3
- HTOHLCKNMRKYLK-KVZSNLRASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]hex Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O HTOHLCKNMRKYLK-KVZSNLRASA-N 0.000 claims description 3
- KPJDVVCDVBFRMU-AREMUKBSSA-N (6r)-6-(2-fluorophenyl)-n-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine Chemical group COCCNCCC1=CC=CC(NC=2N=C3C4=CC=CC=C4[C@H](C=4C(=CC=CC=4)F)CC3=CN=2)=C1 KPJDVVCDVBFRMU-AREMUKBSSA-N 0.000 claims description 3
- LBPKYPYHDKKRFS-UHFFFAOYSA-N 1,5-naphthyridine, 2-[3-(6-methyl-2-pyridinyl)-1h-pyrazol-4-yl]- Chemical compound CC1=CC=CC(C2=C(C=NN2)C=2N=C3C=CC=NC3=CC=2)=N1 LBPKYPYHDKKRFS-UHFFFAOYSA-N 0.000 claims description 3
- GGVFLXSCFPVLMS-WPCLDFDBSA-N 1-(3-azabicyclo[2.2.2]octan-3-yl)-2-[2-(3,5-dimethylphenyl)-3-[(2s)-1-(2-pyridin-4-ylethylamino)propan-2-yl]-1h-indol-5-yl]-2-methylpropan-1-one Chemical compound C([C@@H](C)C=1C2=CC(=CC=C2NC=1C=1C=C(C)C=C(C)C=1)C(C)(C)C(=O)N1C2CCC(CC2)C1)NCCC1=CC=NC=C1 GGVFLXSCFPVLMS-WPCLDFDBSA-N 0.000 claims description 3
- MKVMEJKNLUWFSQ-UHFFFAOYSA-N 1-tert-butyl-3-[6-(2,6-dichlorophenyl)-2-[4-(diethylamino)butylamino]pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound CC(C)(C)NC(=O)NC1=NC2=NC(NCCCCN(CC)CC)=NC=C2C=C1C1=C(Cl)C=CC=C1Cl MKVMEJKNLUWFSQ-UHFFFAOYSA-N 0.000 claims description 3
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 claims description 3
- LWKAWHRSPCHMPJ-UHFFFAOYSA-N 2-fluoro-4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C(F)=C1 LWKAWHRSPCHMPJ-UHFFFAOYSA-N 0.000 claims description 3
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 claims description 3
- DKKLXCRMAXNIJF-UHFFFAOYSA-N 3-(4-benzylpiperidin-1-yl)-1-(7-methoxy-3,5-dihydro-2h-1,4-benzothiazepin-4-yl)propan-1-one;hydrochloride Chemical compound Cl.C1C2=CC(OC)=CC=C2SCCN1C(=O)CCN(CC1)CCC1CC1=CC=CC=C1 DKKLXCRMAXNIJF-UHFFFAOYSA-N 0.000 claims description 3
- QADGBOQVBUXZKO-UHFFFAOYSA-N 4-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalene-2-carbonyl)benzoic acid Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)C1=CC=C(C(O)=O)C=C1 QADGBOQVBUXZKO-UHFFFAOYSA-N 0.000 claims description 3
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 claims description 3
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 claims description 3
- LDXQFZZGVTWFCF-DWUXPROESA-N 6-bromo-5-(methylamino)-2-[[(2s,3r,5r,8r,9r)-3,5,9-trimethyl-2-[(2s)-1-oxo-1-(1h-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1OC2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC(Br)=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 LDXQFZZGVTWFCF-DWUXPROESA-N 0.000 claims description 3
- PKLKSAHANRLKJK-UHFFFAOYSA-N 7-methoxy-4-methyl-3,5-dihydro-2h-1,4-benzothiazepine;hydrochloride Chemical compound Cl.S1CCN(C)CC2=CC(OC)=CC=C21 PKLKSAHANRLKJK-UHFFFAOYSA-N 0.000 claims description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 3
- 239000005886 Chlorantraniliprole Substances 0.000 claims description 3
- MUVGVMUWMAGNSY-YCBKVTMHSA-N Corynoxeine Natural products O=C(OC)/C(=C\OC)/[C@@H]1[C@@H](C=C)CN2[C@H]([C@@]3(C(=O)Nc4c3cccc4)CC2)C1 MUVGVMUWMAGNSY-YCBKVTMHSA-N 0.000 claims description 3
- 241000938605 Crocodylia Species 0.000 claims description 3
- INQUULPXCZAKMS-XKZIYDEJSA-N DEL-22379 Chemical compound C12=CC(OC)=CC=C2NC=C1\C=C(C1=C2)/C(=O)NC1=CC=C2NC(=O)CCN1CCCCC1 INQUULPXCZAKMS-XKZIYDEJSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000012820 MEK1 Inhibitor Substances 0.000 claims description 3
- KPQQGHGDBBJGFA-QNGWXLTQSA-N MK-8353 Chemical group C([C@@](C1)(SC)C(=O)NC=2C=C3C(C=4C=NC(OC(C)C)=CC=4)=NNC3=CC=2)CN1CC(=O)N(CC=1)CCC=1C(C=C1)=CC=C1C=1N=CN(C)N=1 KPQQGHGDBBJGFA-QNGWXLTQSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims description 3
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims description 3
- VUJYNHRRRJUAHQ-UHFFFAOYSA-N N-(1,3-dihydroxypropan-2-yloxy)-7-fluoro-6-(2-fluoro-4-iodoanilino)-1-benzofuran-5-carboxamide Chemical compound OCC(CO)ONC(=O)c1cc2ccoc2c(F)c1Nc1ccc(I)cc1F VUJYNHRRRJUAHQ-UHFFFAOYSA-N 0.000 claims description 3
- DKGYQCPFBWFTHM-FSRHSHDFSA-N N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1H-pyrrole-2-carboxamide hydrochloride Chemical compound Cl.C1=NC(NC(C)C)=CC(C=2C=C(NC=2)C(=O)N[C@H](CO)C=2C=C(Cl)C=CC=2)=C1Cl DKGYQCPFBWFTHM-FSRHSHDFSA-N 0.000 claims description 3
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 claims description 3
- CFQULUVMLGZVAF-OYJDLGDISA-N U0126.EtOH Chemical compound CCO.C=1C=CC=C(N)C=1SC(\N)=C(/C#N)\C(\C#N)=C(/N)SC1=CC=CC=C1N CFQULUVMLGZVAF-OYJDLGDISA-N 0.000 claims description 3
- BEMNJULZEQTDJY-UHFFFAOYSA-N [5-amino-1-(2-methyl-3h-benzimidazol-5-yl)pyrazol-4-yl]-(1h-indol-2-yl)methanone Chemical compound C1=CC=C2NC(C(=O)C=3C=NN(C=3N)C=3C=C4N=C(NC4=CC=3)C)=CC2=C1 BEMNJULZEQTDJY-UHFFFAOYSA-N 0.000 claims description 3
- OZPDXBXSBWNOGC-UHFFFAOYSA-M [Cl-].COC1=CC=2CC[N+]3=C(C=2C=C1)C=C1C=CC=C(C1=C3)OC Chemical compound [Cl-].COC1=CC=2CC[N+]3=C(C=2C=C1)C=C1C=CC=C(C1=C3)OC OZPDXBXSBWNOGC-UHFFFAOYSA-M 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- FOIVPCKZDPCJJY-JQIJEIRASA-N arotinoid acid Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C1=CC=C(C(O)=O)C=C1 FOIVPCKZDPCJJY-JQIJEIRASA-N 0.000 claims description 3
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 claims description 3
- 210000000601 blood cell Anatomy 0.000 claims description 3
- 229960001948 caffeine Drugs 0.000 claims description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 3
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 3
- 229960002242 chlorocresol Drugs 0.000 claims description 3
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 claims description 3
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims description 3
- 229950010575 cobimetinib hemifumarate Drugs 0.000 claims description 3
- 229940125810 compound 20 Drugs 0.000 claims description 3
- 210000001608 connective tissue cell Anatomy 0.000 claims description 3
- 229940069586 derazantinib Drugs 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 229950003662 fenretinide Drugs 0.000 claims description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims description 3
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims description 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims description 3
- 229940039009 isoproterenol Drugs 0.000 claims description 3
- MFIHSKBTNZNJIK-UHFFFAOYSA-N medioresinol dimethyl ether Natural products C1=C(OC)C(OC)=CC=C1C1C(COC2C=3C=C(OC)C(OC)=C(OC)C=3)C2CO1 MFIHSKBTNZNJIK-UHFFFAOYSA-N 0.000 claims description 3
- MUVGVMUWMAGNSY-KAXDATADSA-N methyl (e)-2-[(3r,6'r,7's,8'as)-6'-ethenyl-2-oxospiro[1h-indole-3,1'-3,5,6,7,8,8a-hexahydro-2h-indolizine]-7'-yl]-3-methoxyprop-2-enoate Chemical compound O=C1NC2=CC=CC=C2[C@]21CCN1[C@H]2C[C@H](\C(=C/OC)C(=O)OC)[C@@H](C=C)C1 MUVGVMUWMAGNSY-KAXDATADSA-N 0.000 claims description 3
- 210000003632 microfilament Anatomy 0.000 claims description 3
- KSERXGMCDHOLSS-LJQANCHMSA-N n-[(1s)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxamide Chemical compound C1=NC(NC(C)C)=CC(C=2C=C(NC=2)C(=O)N[C@H](CO)C=2C=C(Cl)C=CC=2)=C1Cl KSERXGMCDHOLSS-LJQANCHMSA-N 0.000 claims description 3
- KSERXGMCDHOLSS-UHFFFAOYSA-N n-[1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxamide Chemical compound C1=NC(NC(C)C)=CC(C=2C=C(NC=2)C(=O)NC(CO)C=2C=C(Cl)C=CC=2)=C1Cl KSERXGMCDHOLSS-UHFFFAOYSA-N 0.000 claims description 3
- ILUKRINUNLAVMH-UHFFFAOYSA-N n-[2-[[2-[(2-methoxy-5-methylpyridin-4-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]-5-methylphenyl]prop-2-enamide Chemical compound C1=NC(OC)=CC(NC=2N=C(NC=3C(=CC(C)=CC=3)NC(=O)C=C)C(=CN=2)C(F)(F)F)=C1C ILUKRINUNLAVMH-UHFFFAOYSA-N 0.000 claims description 3
- RDSACQWTXKSHJT-UHFFFAOYSA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide Chemical compound C1CC1(CC(O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-UHFFFAOYSA-N 0.000 claims description 3
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 claims description 3
- 229940121317 pemigatinib Drugs 0.000 claims description 3
- 229950008933 refametinib Drugs 0.000 claims description 3
- 230000035807 sensation Effects 0.000 claims description 3
- JFBMSTWZURKQOC-UHFFFAOYSA-M sodium 2-amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoate Chemical compound [Na+].N12C=CC=CC2=C(OC)C(C)=C1C(=O)C1=CC=C(N)C(C([O-])=O)=C1 JFBMSTWZURKQOC-UHFFFAOYSA-M 0.000 claims description 3
- 229960005314 suramin Drugs 0.000 claims description 3
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 claims description 3
- 229960004066 trametinib Drugs 0.000 claims description 3
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical group CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 3
- 229950008878 ulixertinib Drugs 0.000 claims description 3
- BVRGQPJKSKKGIH-PUAOIOHZSA-N (2R)-2-[5-[5-chloro-2-(oxan-4-ylamino)pyrimidin-4-yl]-3-oxo-1H-isoindol-2-yl]-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide Chemical compound ClC=1C(=NC(=NC=1)NC1CCOCC1)C1=CC=C2CN(C(C2=C1)=O)[C@@H](C(=O)N[C@H](CO)C1=CC(=CC(=C1)OC)F)C BVRGQPJKSKKGIH-PUAOIOHZSA-N 0.000 claims description 2
- MNYBEULOKRVZKY-TZOAMJEDSA-N (2e,4e)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoic acid Chemical compound COC(C)(C)CCCC(C)C\C=C\C(\C)=C\C(O)=O MNYBEULOKRVZKY-TZOAMJEDSA-N 0.000 claims description 2
- SHGAZHPCJJPHSC-GOWYKSNKSA-N (2e,4e,6e,8e)-9-[3,3-dideuterio-6,6-dimethyl-2-(trideuteriomethyl)cyclohexen-1-yl]-3,7-dimethylnona-2,4,6,8-tetraenoic acid Chemical compound [2H]C([2H])([2H])C1=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)(C)CCC1([2H])[2H] SHGAZHPCJJPHSC-GOWYKSNKSA-N 0.000 claims description 2
- HNODNXQAYXJFMQ-LQUSFLDPSA-N (2e,4e,6z)-3-methyl-7-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)octa-2,4,6-trienoic acid Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(\C(C)=C/C=C/C(/C)=C/C(O)=O)C(OCCC)=C2 HNODNXQAYXJFMQ-LQUSFLDPSA-N 0.000 claims description 2
- BHIBZAZKKARFIM-XRYBSMBUSA-N (2e,4e,6z)-7-[3,5-ditert-butyl-2-(2,2-difluoroethoxy)phenyl]-3-methylocta-2,4,6-trienoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(\C)C1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1OCC(F)F BHIBZAZKKARFIM-XRYBSMBUSA-N 0.000 claims description 2
- PPGNMFUMZSAZCW-VOYUZAMQSA-N (2e,4e,6z,8e)-8-(3,4-dihydro-2h-naphthalen-1-ylidene)-3,7-dimethylocta-2,4,6-trienoic acid Chemical compound C1=CC=C2C(=C/C(/C)=C\C=C\C(\C)=C\C(O)=O)/CCCC2=C1 PPGNMFUMZSAZCW-VOYUZAMQSA-N 0.000 claims description 2
- APJSHECCIRQQDV-ZRDIBKRKSA-N (e)-3-[4-hydroxy-3-(5,5,8,8-tetramethyl-3-pentoxy-6,7-dihydronaphthalen-2-yl)phenyl]prop-2-enoic acid Chemical compound CCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1=CC(\C=C\C(O)=O)=CC=C1O APJSHECCIRQQDV-ZRDIBKRKSA-N 0.000 claims description 2
- RAMUASXTSSXCMB-UHFFFAOYSA-N 3-bromo-N-{2-bromo-4-chloro-6-[(1-cyclopropylethyl)carbamoyl]phenyl}-1-(3-chloropyridin-2-yl)-1H-pyrazole-5-carboxamide Chemical compound C1CC1C(C)NC(=O)C1=CC(Cl)=CC(Br)=C1NC(=O)C1=CC(Br)=NN1C1=NC=CC=C1Cl RAMUASXTSSXCMB-UHFFFAOYSA-N 0.000 claims description 2
- AANFHDFOMFRLLR-IBGZPJMESA-N 3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acid Chemical compound O=C([C@@H](O)C=1C=C2C(C)(C)CCC(C2=CC=1)(C)C)NC1=CC=C(C(O)=O)C=C1F AANFHDFOMFRLLR-IBGZPJMESA-N 0.000 claims description 2
- HXBKPYIEQLLNBK-UHFFFAOYSA-N 4-(4-octylphenyl)benzoic acid Chemical compound C1=CC(CCCCCCCC)=CC=C1C1=CC=C(C(O)=O)C=C1 HXBKPYIEQLLNBK-UHFFFAOYSA-N 0.000 claims description 2
- DLFBCHSYAZBTSS-UHFFFAOYSA-N 4-(5,7,7,10,10-pentamethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)benzoic acid Chemical compound C12=CC(C(CCC3(C)C)(C)C)=C3C=C2N(C)C2=CC=CC=C2N=C1C1=CC=C(C(O)=O)C=C1 DLFBCHSYAZBTSS-UHFFFAOYSA-N 0.000 claims description 2
- SQYRBODOBCAROZ-UHFFFAOYSA-N 4-[(6-methyl-2-phenyl-5-prop-2-enylpyrimidin-4-yl)amino]benzoic acid Chemical compound C=CCC=1C(C)=NC(C=2C=CC=CC=2)=NC=1NC1=CC=C(C(O)=O)C=C1 SQYRBODOBCAROZ-UHFFFAOYSA-N 0.000 claims description 2
- FOUVTBKPJRMLPE-FMIVXFBMSA-N 4-[(e)-3-(3,5-ditert-butylphenyl)-3-oxoprop-1-enyl]benzoic acid Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC(C(=O)\C=C\C=2C=CC(=CC=2)C(O)=O)=C1 FOUVTBKPJRMLPE-FMIVXFBMSA-N 0.000 claims description 2
- OQVLOWLEEHYBJH-UHFFFAOYSA-N 4-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethynyl]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C#CC1=CC=C(C(O)=O)C=C1 OQVLOWLEEHYBJH-UHFFFAOYSA-N 0.000 claims description 2
- HSAOETBFVAWNRP-UHFFFAOYSA-N 4-[4-(2-butoxyethoxy)-5-methyl-1,3-thiazol-2-yl]-2-fluorobenzoic acid Chemical compound S1C(C)=C(OCCOCCCC)N=C1C1=CC=C(C(O)=O)C(F)=C1 HSAOETBFVAWNRP-UHFFFAOYSA-N 0.000 claims description 2
- VCQGNUWOMLYNNG-UHFFFAOYSA-N 4-[7-(1-adamantyl)-6-hydroxynaphthalen-2-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=C(O)C(=C2)C34CC5CC(CC(C5)C3)C4)C2=C1 VCQGNUWOMLYNNG-UHFFFAOYSA-N 0.000 claims description 2
- VKSOBFJVOGQQMY-UHFFFAOYSA-N 4-chloro-3-methylphenol Chemical compound CC1=CC(O)=CC=C1Cl.CC1=CC(O)=CC=C1Cl VKSOBFJVOGQQMY-UHFFFAOYSA-N 0.000 claims description 2
- SZWKGOZKRMMLAJ-UHFFFAOYSA-N 4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C(=O)NC1=CC=C(C(O)=O)C=C1 SZWKGOZKRMMLAJ-UHFFFAOYSA-N 0.000 claims description 2
- KEEHJLBAOLGBJZ-WEDZBJJJSA-N 5,6-epoxyretinoic acid Chemical compound C1CCC(C)(C)C2(/C=C/C(/C)=C/C=C/C(/C)=C/C(O)=O)C1(C)O2 KEEHJLBAOLGBJZ-WEDZBJJJSA-N 0.000 claims description 2
- URUSABQSUCBGGJ-UHFFFAOYSA-N 5-(5,5,8,8-tetramethyl-6,7-dihydroanthracen-2-yl)thiophene-3-carboxylic acid Chemical compound C=1C=C2C=C3C(C)(C)CCC(C)(C)C3=CC2=CC=1C1=CC(C(O)=O)=CS1 URUSABQSUCBGGJ-UHFFFAOYSA-N 0.000 claims description 2
- VUODRPPTYLBGFM-CMDGGOBGSA-N BMS-453 Chemical compound C12=CC(\C=C\C=3C=CC(=CC=3)C(O)=O)=CC=C2C(C)(C)CC=C1C1=CC=CC=C1 VUODRPPTYLBGFM-CMDGGOBGSA-N 0.000 claims description 2
- LDGIHZJOIQSHPB-UHFFFAOYSA-N CD437 Chemical compound C1C(C2)CC(C3)CC2CC13C1=CC(C2=CC3=CC=C(C=C3C=C2)C(=O)O)=CC=C1O LDGIHZJOIQSHPB-UHFFFAOYSA-N 0.000 claims description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 2
- 229940096885 Retinoic acid receptor agonist Drugs 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229960002916 adapalene Drugs 0.000 claims description 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 2
- KGUMXGDKXYTTEY-FRCNGJHJSA-N all-trans-4-hydroxyretinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(O)CCC1(C)C KGUMXGDKXYTTEY-FRCNGJHJSA-N 0.000 claims description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 2
- 239000011717 all-trans-retinol Substances 0.000 claims description 2
- 229940100609 all-trans-retinol Drugs 0.000 claims description 2
- 235000019169 all-trans-retinol Nutrition 0.000 claims description 2
- 235000013734 beta-carotene Nutrition 0.000 claims description 2
- 239000011648 beta-carotene Substances 0.000 claims description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 2
- 229960002747 betacarotene Drugs 0.000 claims description 2
- 150000001746 carotenes Chemical class 0.000 claims description 2
- 235000005473 carotenes Nutrition 0.000 claims description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 2
- 235000012661 lycopene Nutrition 0.000 claims description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 2
- 239000001751 lycopene Substances 0.000 claims description 2
- 229960004999 lycopene Drugs 0.000 claims description 2
- 229960002371 pentifylline Drugs 0.000 claims description 2
- 229930002330 retinoic acid Natural products 0.000 claims description 2
- 229960000342 retinol acetate Drugs 0.000 claims description 2
- 235000019173 retinyl acetate Nutrition 0.000 claims description 2
- 239000011770 retinyl acetate Substances 0.000 claims description 2
- 230000001502 supplementing effect Effects 0.000 claims description 2
- 229960000621 suramin sodium Drugs 0.000 claims description 2
- KNDVJPKNBVIKML-UHFFFAOYSA-N tetraniliprole Chemical compound CNC(=O)C1=CC(C#N)=CC(C)=C1NC(=O)C1=CC(CN2N=C(N=N2)C(F)(F)F)=NN1C1=NC=CC=C1Cl KNDVJPKNBVIKML-UHFFFAOYSA-N 0.000 claims description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 2
- RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 claims description 2
- FEBNTWHYQKGEIQ-SUKRRCERSA-N valerenic acid Chemical compound C[C@@H]1CC[C@@H](\C=C(/C)C(O)=O)C2=C(C)CC[C@H]12 FEBNTWHYQKGEIQ-SUKRRCERSA-N 0.000 claims description 2
- FUHPCDQQVWLRRY-UHFFFAOYSA-N valerenic acid Natural products CC1CCC(C=C(/C)C(=O)O)C2C1CC=C2C FUHPCDQQVWLRRY-UHFFFAOYSA-N 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 2
- QSRQAKVNYDAVIT-UHFFFAOYSA-N 1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)benzotriazole-5-carboxylic acid Chemical compound N1=NC2=CC(C(O)=O)=CC=C2N1C1=CC(C(C)(C)CCC2(C)C)=C2C=C1C QSRQAKVNYDAVIT-UHFFFAOYSA-N 0.000 claims 1
- 210000004940 nucleus Anatomy 0.000 description 47
- 238000011282 treatment Methods 0.000 description 40
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 23
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 239000012824 ERK inhibitor Substances 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 241000287828 Gallus gallus Species 0.000 description 14
- 230000004913 activation Effects 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 11
- 238000011002 quantification Methods 0.000 description 11
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 10
- 241000283690 Bos taurus Species 0.000 description 10
- 230000021268 myoblast fusion Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 210000004504 adult stem cell Anatomy 0.000 description 8
- 239000007640 basal medium Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- YJIYWYAMZFVECX-UHFFFAOYSA-N 2-[N-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]anilino]acetic acid acetyloxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O YJIYWYAMZFVECX-UHFFFAOYSA-N 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000011278 co-treatment Methods 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000035800 maturation Effects 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 208000031074 Reinjury Diseases 0.000 description 4
- 210000002459 blastocyst Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000002894 multi-fate stem cell Anatomy 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 230000022379 skeletal muscle tissue development Effects 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 101150003028 Hprt1 gene Proteins 0.000 description 3
- 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002340 cardiotoxin Substances 0.000 description 3
- 231100000677 cardiotoxin Toxicity 0.000 description 3
- 230000002380 cytological effect Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000000799 fusogenic effect Effects 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013622 meat product Nutrition 0.000 description 3
- 230000009756 muscle regeneration Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- XHOJEECXVUMYMF-IQGLISFBSA-N (2R)-2-[5-[5-chloro-2-(oxan-4-ylamino)pyrimidin-4-yl]-3-oxo-1H-isoindol-2-yl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]propanamide Chemical compound ClC=1C(=NC(=NC=1)NC1CCOCC1)C1=CC=C2CN(C(C2=C1)=O)[C@@H](C(=O)N[C@H](CO)C1=CC(=CC=C1)C)C XHOJEECXVUMYMF-IQGLISFBSA-N 0.000 description 2
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 229930001406 Ryanodine Natural products 0.000 description 2
- 230000002293 adipogenic effect Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000009744 cell cycle exit Effects 0.000 description 2
- 230000002648 chondrogenic effect Effects 0.000 description 2
- 229960001987 dantrolene Drugs 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- JJSYXNQGLHBRRK-SFEDZAPPSA-N ryanodine Chemical compound O([C@@H]1[C@]([C@@]2([C@]3(O)[C@]45O[C@@]2(O)C[C@]([C@]4(CC[C@H](C)[C@H]5O)O)(C)[C@@]31O)C)(O)C(C)C)C(=O)C1=CC=CN1 JJSYXNQGLHBRRK-SFEDZAPPSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 1
- HVIGNZUDBVLTLU-MRXNPFEDSA-N (6R)-7-[(3,4-difluorophenyl)methyl]-6-(methoxymethyl)-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C[C@@H]2COC)C=C(N=3)C2=NC(=NC=C2C)NC2=CC=NN2C)=O)C=CC=1F HVIGNZUDBVLTLU-MRXNPFEDSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 229940125927 AZD0364 Drugs 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 229940043709 CaM kinase II inhibitor Drugs 0.000 description 1
- 239000012657 CaMKII inhibitor Substances 0.000 description 1
- 102100024153 Cadherin-15 Human genes 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000003727 Caveolin 1 Human genes 0.000 description 1
- 108090000026 Caveolin 1 Proteins 0.000 description 1
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 101100458289 Drosophila melanogaster msps gene Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100032832 Integrin alpha-7 Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102100026040 Leishmanolysin-like peptidase Human genes 0.000 description 1
- 108010018562 M-cadherin Proteins 0.000 description 1
- 230000005723 MEK inhibition Effects 0.000 description 1
- 101150039183 MYF6 gene Proteins 0.000 description 1
- 101150013833 MYOD1 gene Proteins 0.000 description 1
- 102100038380 Myogenic factor 5 Human genes 0.000 description 1
- 108010056785 Myogenin Proteins 0.000 description 1
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 1
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 1
- 108050003738 Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101100025373 Notophthalmus viridescens MYF-5 gene Proteins 0.000 description 1
- 241001327647 Oncorhynchus mykiss gairdneri Species 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- NHJSWORVNIOXIT-UHFFFAOYSA-N PD-166866 Chemical compound COC1=CC(OC)=CC(C=2C(=NC3=NC(N)=NC=C3C=2)NC(=O)NC(C)(C)C)=C1 NHJSWORVNIOXIT-UHFFFAOYSA-N 0.000 description 1
- 101800001386 Peptide II Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 229940121908 Retinoid X receptor agonist Drugs 0.000 description 1
- 101150097537 Ryr1 gene Proteins 0.000 description 1
- 208000034177 Self-improving collodion baby Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101150071798 TNNT3 gene Proteins 0.000 description 1
- 101100239689 Takifugu rubripes myod gene Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101100239691 Xenopus laevis myod1-a gene Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000003683 corneal stroma Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 239000002803 fossil fuel Substances 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 108010024084 integrin alpha7 Proteins 0.000 description 1
- 108010092830 integrin alpha7beta1 Proteins 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- MCPLVIGCWWTHFH-UHFFFAOYSA-L methyl blue Chemical compound [Na+].[Na+].C1=CC(S(=O)(=O)[O-])=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[NH+]C=2C=CC(=CC=2)S([O-])(=O)=O)C=2C=CC(NC=3C=CC(=CC=3)S([O-])(=O)=O)=CC=2)C=C1 MCPLVIGCWWTHFH-UHFFFAOYSA-L 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008186 parthenogenesis Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- 208000003665 self-healing collodion baby Diseases 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000000419 skeletal muscle satellite cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002287 time-lapse microscopy Methods 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/40—Meat products; Meat meal; Preparation or treatment thereof containing additives
- A23L13/45—Addition of, or treatment with, microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL283011A IL283011A (en) | 2021-05-06 | 2021-05-06 | Methods for creating hypertrophic muscle fibers for industrial meat preparation |
| US202163283242P | 2021-11-25 | 2021-11-25 | |
| PCT/IL2022/050474 WO2022234586A1 (fr) | 2021-05-06 | 2022-05-05 | Procédé d'induction de fibres musculaires hypertrophique pour la production industrielle de viande |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308274A true IL308274A (en) | 2024-01-01 |
Family
ID=81750912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308274A IL308274A (en) | 2021-05-06 | 2022-05-05 | A method for creating hypertrophic muscle fibers to create industrial meat |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240074473A1 (fr) |
| EP (1) | EP4334436A1 (fr) |
| AU (1) | AU2022269414A1 (fr) |
| BR (1) | BR112023022889A2 (fr) |
| CA (1) | CA3216903A1 (fr) |
| IL (1) | IL308274A (fr) |
| WO (1) | WO2022234586A1 (fr) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998030679A1 (fr) | 1997-01-10 | 1998-07-16 | Life Technologies, Inc. | Substitut de serum pour cellules souches embryonnaires |
| WO1999031222A1 (fr) | 1997-12-18 | 1999-06-24 | Willem Frederik Van Eelen | PRODUCTION DE VIANDE A L'ECHELLE INDUSTRIELLE A PARTIR DE CULTURES CELLULAIRES $i(IN VITRO) |
| US8354277B2 (en) | 2004-10-12 | 2013-01-15 | Technion Research & Development Foundation Ltd. | Isolated primate embryonic cells derived from extended blastocysts |
| CN111154726A (zh) | 2013-10-30 | 2020-05-15 | 密苏里大学的策展人 | 可扩展性骨骼肌谱系特化和培育的方法 |
| JP2017525351A (ja) * | 2014-07-30 | 2017-09-07 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． | 多能性幹細胞の培養用培地 |
| EP3202894A4 (fr) | 2014-09-29 | 2018-05-23 | Public University Corporation Yokohama City University | Procédé de production d'agrégats de cellules en trois dimensions |
| AU2017208094A1 (en) | 2016-01-14 | 2018-08-09 | Upside Foods, Inc. | Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process |
| IL302693A (en) | 2016-07-11 | 2023-07-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Methods and systems for growing cells in culture |
| CN110730615A (zh) | 2017-04-09 | 2020-01-24 | 超级肉类肉本质有限公司 | 含培养肉的混合食品 |
| WO2018208628A1 (fr) | 2017-05-06 | 2018-11-15 | Memphis Meats, Inc. | Compositions et procédés permettant d'augmenter la densité de culture d'une biomasse cellulaire dans une infrastructure de culture |
| CA3066060A1 (fr) | 2017-06-07 | 2018-12-13 | Wild Type, Inc. | Production de chair ex vivo |
| KR20200071061A (ko) | 2017-07-15 | 2020-06-18 | 알레프 팜스 리미티드 | 배양된 육류 조성물 |
| US10543827B2 (en) | 2017-08-30 | 2020-01-28 | Westinghouse Air Brake Technologies Corporation | System for accessing integral pressures of brake control valve |
| US10669524B2 (en) | 2018-06-12 | 2020-06-02 | Fork & Goode, Inc. | Large scale cell culture system for making meat and associated products |
| EP3852742A1 (fr) * | 2018-09-18 | 2021-07-28 | Société des Produits Nestlé S.A. | Composés inhibiteurs de la kinase raf-1 pour la modulation du muscle squelettique, procédés et utilisations de ceux-ci |
| WO2020131661A1 (fr) * | 2018-12-21 | 2020-06-25 | Trustees of Tuffs College | Muscle d'insecte in vitro en tant que source de nutrition |
| BR112021012871A8 (pt) | 2019-02-01 | 2023-04-11 | Nanofiber Solutions Llc | Produto de carne cultivado e método para produzir um produto de carne cultivado |
| US20220195392A1 (en) * | 2019-04-23 | 2022-06-23 | The Regents Of The University Of California | Methods and compositions for cell culture on heterogeneous scaffolds |
| WO2020237021A1 (fr) | 2019-05-21 | 2020-11-26 | Kent State University | Lignées cellulaires animales pour aliments contenant des cellules animales cultivées |
| CA3140450A1 (fr) | 2019-06-14 | 2020-12-17 | Nicholas Mullen | Produit alimentaire aviaire in vitro |
-
2022
- 2022-05-05 IL IL308274A patent/IL308274A/en unknown
- 2022-05-05 AU AU2022269414A patent/AU2022269414A1/en active Pending
- 2022-05-05 CA CA3216903A patent/CA3216903A1/fr active Pending
- 2022-05-05 BR BR112023022889A patent/BR112023022889A2/pt unknown
- 2022-05-05 EP EP22724927.3A patent/EP4334436A1/fr active Pending
- 2022-05-05 WO PCT/IL2022/050474 patent/WO2022234586A1/fr active Application Filing
-
2023
- 2023-11-06 US US18/387,165 patent/US20240074473A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3216903A1 (fr) | 2022-11-10 |
| BR112023022889A2 (pt) | 2024-01-23 |
| AU2022269414A1 (en) | 2023-12-14 |
| US20240074473A1 (en) | 2024-03-07 |
| WO2022234586A1 (fr) | 2022-11-10 |
| EP4334436A1 (fr) | 2024-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024040143A (ja) | 多能性哺乳動物幹細胞に由来する心筋細胞を成熟させるための培地組成物 | |
| US20070087437A1 (en) | Methods for rejuvenating cells in vitro and in vivo | |
| CN102186969A (zh) | 由人多能干细胞制备人皮肤替代品的方法 | |
| Coste et al. | Human bone marrow harbors cells with neural crest-associated characteristics like human adipose and dermis tissues | |
| US20240189363A1 (en) | Cardiomyocytes and compositions and methods for producing the same | |
| Tan et al. | Retinoic acid promotes the proliferation of primordial germ cell–like cells differentiated from mouse skin-derived stem cells in vitro | |
| CN106282100A (zh) | 一种纯化牛胎儿骨骼肌组织来源前体脂肪细胞的方法 | |
| KR20160145170A (ko) | 피부 유래 전구 세포의 제작 방법 | |
| Yuen Jr et al. | Perspectives on scaling production of adipose tissue for food applications | |
| Jara et al. | Stem cell-based strategies and challenges for production of cultivated meat | |
| Seyedi et al. | Suspension culture alters insulin secretion in induced human umbilical cord matrix-derived mesenchymal cells | |
| Di Foggia et al. | Isolation of satellite cells from single muscle fibers from young, aged, or dystrophic muscles | |
| IL308274A (en) | A method for creating hypertrophic muscle fibers to create industrial meat | |
| US20100099189A1 (en) | Methods for Rejuvenating Cells In Vitro and In Vivo | |
| CN117529550A (zh) | 心肌细胞和组合物以及用于生产它们的方法 | |
| Kim et al. | Characteristics of bovine muscle satellite cell from different breeds for efficient production of cultured meat | |
| Shibota et al. | Larval-to-adult conversion of a myogenic system in the frog, Xenopus laevis, by larval-type myoblast-specific control of cell division, cell differentiation, and programmed cell death by triiodo-L-thyronine | |
| Wei et al. | Bovine mature adipocytes readily return to a proliferative state | |
| WO2020205464A1 (fr) | Cellules de follicules ovariens et constructions pour le traitement de la fertilité et une hormonothérapie substitutive | |
| US20130224782A1 (en) | Neurogenesis screening method and system using adipose tissue derived stem cells | |
| Tong et al. | Comparison and analysis of Wuding and avian chicken skeletal muscle satellite cells | |
| WO2012071108A1 (fr) | Cellules pluripotentes dérivées de cellules somatiques et procédés d'utilisation de celles-ci | |
| US9428730B2 (en) | Coatings and culture media for promoting neurogenesis in adipose tissue derived stem cells | |
| CN117580943A (zh) | 用于工业肉类生产的诱导肥大肌纤维的方法 | |
| CA3070750A1 (fr) | Cellules pancreatiques fonctionnelles de felinsprovenant de tissu adipeux |